Education
About Us
Working with TipRanks
Follow Us
MindWalk Holdings (DE:TQB0)
FRANKFURT:TQB0
Earnings Data
Report Date
Jul 23, 2026TBA (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
-0.04Last Year’s EPS
-0.03Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and scientific positives: robust revenue growth (Q3 +52% YoY, nine-month +45%), U.S. revenue doubling, the signing of the first enterprise recurring Lens AI platform contract, important preclinical pipeline discoveries (conserved dengue epitope, influenza conserved feature, GLP-1 activity vs semaglutide), peer-reviewed validation, and a new nanobody platform launch. Offsetting these strengths are higher operating expenses (notably S&M and R&D), a Q3 gross margin dip, ongoing net losses and cash burn ($10.1M YTD), and dependency on pending preclinical readouts and successful asset-level financing. Overall, the highlights—revenue acceleration, platform monetization, and differentiated scientific milestones—materially outweigh the lowlights tied to investment-driven losses and program-stage risk.Company Guidance
Strong Revenue Growth and U.S. Expansion
Q3 revenue of $4.2M, up 52% year over year from $2.7M. Nine-month revenue of $11.4M, up 45% versus $7.9M prior year. U.S. revenue doubled year over year to $2.6M (from $1.3M), reflecting strategic investments in Boston/Cambridge and North American commercial focus.
First Enterprise Lens AI Platform Contract — Recurring Revenue
Signed first one-year enterprise Lens AI platform contract structured as monthly recurring revenue, marking a shift from primarily project-based revenue toward a contracted, scalable enterprise SaaS model. Lens AI is being rolled out across the broader client base (~750 active clients).
Pipeline Milestones — Dengue Discovery
HIFT identified a single conserved functional epitope across all four dengue serotypes (a discontinuous epitope invisible to sequence alignment). Rabbit immunizations completed; binding confirmation expected imminently, then multiserotype neutralization testing — dengue positioned as near-term proof of concept.
Pipeline Milestones — Influenza and GLP-1 Progress
Influenza: screened >2,000 diverse sequences and identified a single conserved functional feature across all sequences; moving toward manufacturing of in silico lead candidate. GLP-1: independent third-party in vitro assay confirmed receptor activation with activity relative to semaglutide; a dual regimen linking GLP-1 to a second longevity pathway was also identified.
Platform & IP Strength — HIFT and Functional Adjacency
HIFT (patented biological representation) highlighted as a unique, non-sequence-based approach operating on invariant functional architecture. Advanced functional adjacency capability (identifying molecules with same therapeutic effect despite low sequence similarity) and initiated IP protection on that capability.
Peer-Reviewed Validation and New Platform Launch
Published peer-reviewed work in Biomacromolecules demonstrating wet lab nanobody discovery capabilities. Launched B Cell LAMA single B cell nanobody discovery platform; company claims functional (not just affinity) selection yields superior multivalent potency. Company also notes 15 molecules advanced to clinic across portfolio.
Improved YTD Gross Margin and Cash Position
Nine-month gross margin improved to 58% from 53% a year ago (+5 percentage points). Company ended Q3 with $14.2M in cash and reports cash used in operations of $10.1M YTD, with divestiture proceeds from Netherlands redeployed into commercial growth and pipeline development.
DE:TQB0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:TQB0 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 12, 2026 | €1.10 | €1.16 | +5.45% |
Dec 15, 2025 | €1.52 | €1.47 | -3.29% |
Sep 15, 2025 | €1.78 | €1.67 | -6.46% |
Jul 29, 2025 | €1.77 | €1.78 | +0.56% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does MindWalk Holdings (DE:TQB0) report earnings?
MindWalk Holdings (DE:TQB0) is schdueled to report earning on Jul 23, 2026, TBA (Confirmed).
What is MindWalk Holdings (DE:TQB0) earnings time?
MindWalk Holdings (DE:TQB0) earnings time is at Jul 23, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of MindWalk Holdings stock?
The P/E ratio of MindWalk Holdings is N/A.
What is DE:TQB0 EPS forecast?
DE:TQB0 EPS forecast for the fiscal quarter 2026 (Q4) is -0.04.